• Since the discovery of SNCA, several genes have been found that can cause PD1,2
  • Studies of families with high rates of PD, as well as twin studies, have been used to identify genetic factors that contribute to the development of PD, including monogenic causes1,2 

SNCA=α-synuclein; PD=Parkinson’s disease

Access Slide Deck: Parkinson’s disease – Neurobiology and aetiology

file_download Download in HQ
Published 03.06.2025
Permissions
Published 03.06.2025
Permissions

Related content

image Image Graphic showing extracellular, multimerization, and intracellular targets of alpha-synuclein for therapeutic intervention in Parkinson’s disease
Possible α-synuclein targets for development of therapies for Parkinson’s disease

Overview of three therapeutic strategies targeting alpha-synuclein in the development of disease-modifying treatments for Parkinson’s disease

26.06.2025 Parkinson’s Disease
image Image Chart showing progression of functional decline in Parkinson’s disease with different treatment approaches, from symptomatic benefit to disease modification.
Disease modification in Parkinson’s disease

Graphical representation of how various treatment strategies can impact disease progression in Parkinson’s disease, from symptom relief to potential cure

26.06.2025 Parkinson’s Disease
image Image Diagram showing how COMT inhibitors block the conversion of L-DOPA to 3-OMD, enhancing dopamine levels in the synapse in Parkinson’s disease.
Catechol-O-methyltransferase (COMT) inhibitors mechanism of action

Illustration of how COMT inhibitors increase dopamine availability in Parkinson’s disease by preventing the breakdown of L-DOPA

26.06.2025 Parkinson’s Disease